H3K14ac polyclonal antibody - Classic

Catalog Number
50 μg
  Bulk order
Other format

Polyclonal antibody raised in rabbit against the region of histone H3 containing the acetylated lysine 14 (H3K14ac), using a KLH-conjugated synthetic peptide.

Concentration0.9 µg/µl
Species reactivityHuman
PurityAffinity purified
PrecautionsThis product is for research use only. Not for use in diagnostic or therapeutic procedures.
Applications Suggested dilution * References
ChIP * 2 μg/ChIP Fig 1
ELISA 1:1,000 - 1:5,000 Fig 3
Dot Blotting 1:10,000 Fig 3
Western Blotting 1:1,000 Fig 4

* Please note that the optimal antibody amount per IP should be determined by the end-user. We recommend testing 1-5 μg per IP.

PROMOTION Epistore - 10% OFF (valid until: March 31, 2017)

*Option to pay via PO or credit card

  • Batch-specific Validation Data


    Figure 1. ChIP results obtained with the Diagenode antibody directed against H3K14ac
    ChIP assays were performed using human HeLa cells, the Diagenode antibody against H3K14ac (cat. No. C15410310) and optimized PCR primer sets for qPCR. ChIP was performed with the “iDeal ChIP-seq” kit (cat. No. C01010055), using sheared chromatin from 1.5 million cells. A titration of the antibody consisting of 0.5, 1, 2 and 5 μg per ChIP experiment was analysed. IgG (1 μg/IP) was used as negative IP control. QPCR was performed with primers for a region approximately 1 kb upstream of the ACTB and GAPDH promoters, used as positive controls, and for the coding region of the inactive MYOD1 gene and the Sat2 satellite repeat, used as negative controls. Figure 1 shows the recovery, expressed as a % of input (the relative amount of immunoprecipitated DNA compared to input DNA after qPCR analysis).


    Figure 2. Determination of the antibody titer
    To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against H3K14ac (cat. No. C15410310) in antigen coated wells. The antigen used was a peptide containing the histone modification of interest. By plotting the absorbance against the antibody dilution (Figure 2), the titer of the antibody was estimated to be 1:73,200.

    Cross reactivity

    Figure 3. Cross reactivity tests using the Diagenode antibody directed against H3K14ac
    To test the cross reactivity of the Diagenode antibody against H3K14ac (cat. No. C15410310), a Dot Blot analysis was performed with peptides containing other histone modifications and the unmodified H3K14. One hundred to 0.2 pmol of the respective peptides were spotted on a membrane. The antibody was used at a dilution of 1:10,000. Figure 3 shows a high specificity of the antibody for the modification of interest.

    Western blot

    Figure 4. Western blot analysis using the Diagenode antibody directed against H3K14ac
    Western blot was performed on whole cell (25 μg, lane 1) and histone extracts (15 μg, lane 2) from HeLa cells, and on 1 μg of recombinant histone H2A, H2B, H3 and H4 (lane 3, 4, 5 and 6, respectively) using the Diagenode antibody against H3K14ac (cat. No. C15410310). The antibody was diluted 1:1,000 in TBS-Tween containing 5% skimmed milk. The position of the protein of interest is indicated on the right; the marker (in kDa) is shown on the left.

  • Applications
    Enzyme-linked immunosorbent assay. Read more
    Dot blotting Read more
    Western blot : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies. Learn more about: Load... Read more
    ChIP-qPCR (ab)
    Read more
  • Documents
    Datasheet H3K14ac C15410310 DATASHEET
    Datasheet description
  • Publications

    How to properly cite this product in your work

    Diagenode strongly recommends using this: H3K14ac polyclonal antibody - Classic (Diagenode Cat# C15410310 Lot# A2283P). Click here to copy to clipboard.

    Using our products in your publication? Let us know!

  • Related products


 See all events

Twitter feed


 See all news